Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects

Diabetes, Obesity and Metabolism

Volumn 12, Issue 3, 2010, Pages 219-223

  Eldor, R ^a   Kidron, M ^a,b   Arbit, E ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Oramed Pharmaceuticals   (Israel)

Author keywords

Diabetes; Glucose; Hepatic glucose metabolism; Oral absorption

Indexed keywords

ADJUVANT; C PEPTIDE; DRUG CARRIER; GLUCOSE; INSULIN;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CAPSULE; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENCAPSULATION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOLUNTEER;

EID: 75649084199     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01153.x     Document Type: Article

References (21)

1. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22. Heart Protection Study Collaborative Group
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The Diabetes C, Complications Trial Research G
4. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
5. Bo S, Ciccone G, Guidi S. Diet or exercise: what is more effective in preventing or reducing metabolic alterations? Eur J Endocrinol 2008, 159:685-691.
6. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995, 44:1249-1258. U.K. Prospective Diabetes Study Group
7. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005, 28:888-894. The Diabetes Prevention Program Research G
8. Nathan DM. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002, 347:1342-1349.
9. Kidron M, Raz I, Kessler K, Wolfensberger M, Schwob H, Schruefer C. 2008, Open-label study to assess the safety, pharmacokinetics (pk) and pharmacodynamics (Pd) of five oral insulin formulations in healthy volunteers. European Association for the Study Of Diabetes (EASD),, Rome
10. Meier JJ, Holst JJ, Schmidt WE, Nauck MA. Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans. Am J Physiol Endocrinol Metab 2007, 293:E849-E856.
11. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992, 41:368-377.
12. De Vos P, De Haan BJ, Vegter D. Insulin levels after portal and systemic insulin infusion differ in a dose-dependent fashion. Horm Metab Res 1998, 30:721-725.
13. Eaton RP, Allen RC, Schade DS. Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion. J Clin Endocrinol Metab 1983, 56:1294-1300.
14. Arbit E. The physiological rationale for oral insulin administration. Diabetes Technol Ther 2004, 6:510-517.
15. Maheux P, Chen YD, Polonsky KS, Reaven GM. Evidence that insulin can directly inhibit hepatic glucose production. Diabetologia 1997, 40:1300-1306.
16. Cherrington AD, Moore MC, Sindelar DK, Edgerton DS. Insulin action on the liver in vivo. Biochem Soc Trans 2007, 35:1171-1174.
17. Jeandidier N, Selam JL, Renard E. Decreased severe hypoglycemia frequency during intraperitoneal insulin infusion using programmable implantable pumps. Diabetes Care 1996, 19:780. Evadiac Study Group
18. Ryan EA, Shandro T, Green K. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004, 53:955-962.
19. Shishko PI, Kovalev PA, Goncharov VG, Zajarny IU. Comparison of peripheral and portal (via the umbilical vein) routes of insulin infusion in IDDM patients. Diabetes 1992, 41:1042-1049.
20. Kidron M, Dinh S, Menachem Y. A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects. Diabet Med 2004, 21:354-357.
21. Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov 2003, 2:289-295.